
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination... BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.0899 | 31.14 | 3.5 | 4.5899 | 3.34 | 51167 | 3.93515623 | CS |
4 | 0.8599 | 23.0536193029 | 3.73 | 4.7809 | 3.34 | 46671 | 3.98749189 | CS |
12 | -1.4101 | -23.5016666667 | 6 | 7.87 | 3 | 409943 | 4.90980942 | CS |
26 | -10.5601 | -69.703630363 | 15.15 | 19.05 | 3 | 956970 | 10.4886334 | CS |
52 | -36.2101 | -88.750245098 | 40.8 | 42.7485 | 3 | 1745834 | 10.77096708 | CS |
156 | -172.4101 | -97.4068361582 | 177 | 178.4985 | 3 | 747059 | 30.92642889 | CS |
260 | -59.0101 | -92.7831761006 | 63.6 | 187.05 | 3 | 1104308 | 65.64360425 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.